Top 10 Global Pharmaceutical Company Awards $4.6 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring and Inf
December 23 2004 - 9:05AM
PR Newswire (US)
Top 10 Global Pharmaceutical Company Awards $4.6 Million in Studies
to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Agreements Extend Franchise
Commitment PHILADELPHIA, Dec. 23 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), a leading provider
of centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has been awarded
approximately $4.6 million in cardiac safety monitoring and
services from a top 10 global pharmaceutical organization for one
of its key drug candidates in late phase clinical trials extending
the franchise agreement signed in September 2003 by $1.6 million.
The award covers two Phase III studies, for which eRT will provide
comprehensive support, including provision of approximately 600
units of digital 12-lead ECG equipment designed to facilitate
collection of cardiac safety data that is subsequently provided to
eRT for analysis. eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT(R) workflow enabled data handling technology,
the first solution in production that was designed explicitly to
meet emerging international regulatory guidance and technical
standards. "With sites distributed across five continents, the
trials represented by these significant agreements illustrate
industry best practice for digital collection, processing and
analysis of cardiac safety data in studies involving significant
target patient populations," said Scott Grisanti, senior vice
president of business development and chief marketing officer at
eRT. "Recent industry events concerning cardiac safety of compounds
already approved for marketing are instructive as to the
significant role of effective cardiac safety monitoring across all
phases of clinical development." Based in Philadelphia, PA,
eResearchTechnology, Inc. (http://www.ert.com/) is a provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10-K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, Inc.,
+1-908-203-6473; or Matt Hayden, Hayden Communications,
+1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Sep 2024 to Oct 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Oct 2023 to Oct 2024